subcutaneously administered monoclonal antibody. They are indicated in the treatment and prevention of bone metastases and skeletal-related events and of osteoporosis in patients receiving hormone therapy. 1 – 6 These agents are also routinely used for
Search Results
Paul S. White, Michael Dennis, Eric A. Jones, Janice M. Weinberg, and Shayna Sarosiek
Karen L. Reckamp
in patients with and without brain metastases, and has less toxicity than either the first- or second-generation EGFR TKIs. Virtually all patients who experience response to frontline EGFR TKI therapy develop resistance. The most common mechanism of
Joe Y. Chang and Vivek Verma
not. 3 , 5 In addition, brain metastases have historically been associated with a poorer prognosis and have been highly underrepresented in existing randomized trials ( Table 1 ); whether these patients receive the same benefit from local therapy as
Presenters: Valencia D. Thomas, Michael K. Wong, and Andrew J. Bishop
, provide an outline for patient stratification based on risk factors for local recurrence, metastases, and death from disease ( Figure 1 ). 2 “There are so many characteristics and elements that we must take into consideration that there are conflicting
Philippe E. Spiess, Simon Horenblas, Lance C. Pagliaro, Matthew C. Biagioli, Juanita Crook, Peter E. Clark, Richard E. Greenberg, and Cesar E. Ercole
adopting a multimodal approach consisting of neoadjuvant systemic chemotherapy followed by consolidative surgical resection in patients presenting with bulky/locally advanced nodal metastases from penile cancer. In 2013, an estimated 1570 new cases of
Himani Aggarwal, Li Li, Gebra Cuyun Carter, Kathy Fraeman, and Ariel Berger
.5%; P =.01), or distant metastases (1.8% vs 9.5%; P =.029) vs HPV-negative patients. Among HPV-positive patients, 75.5%, 12.7%, and 10.9% had squamous cell carcinoma NOS, basaloid squamous cell carcinoma, and squamous cell carcinoma large cell non
Hiram S. Cody III and Kimberly J. Van Zee
; 233 : 537 – 541 . 39 Fourquet A de la Rochfordiere A Campana F . Occult primary breast cancer with axillary metastases . In Harris JR , Lippman ME , Morrow M , Hellman S (eds). Diseases of the Breast. Philadelphia : Lippincott
Melanoma, Version 2.2013
Featured Updates to the NCCN Guidelines
Daniel G. Coit, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson III, Adil Daud, Dominick DiMaio, Martin D. Fleming, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr., Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Anne Lind, Mary C. Martini, Anthony J. Olszanski, Scott K. Pruitt, Merrick I. Ross, Susan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, Marshall M. Urist, Nicole McMillian, and Maria Ho
metastases who would be at higher risk of recurrence and who might be candidates for complete lymph node dissection or adjuvant systemic therapy. A large meta-analysis, including 71 studies and 25,240 participants, estimated the risk of nodal recurrence after
Shankar Sellappan, Adele Blackler, Wei-Li Liao, Emily O'Day, Peng Xu, Sheeno Thyparambil, Fabiola Cecchi, Todd Hembrough, and Daniel V.T. Catenacci
improve clinical outcomes. Case Presentation A 39-year-old man was diagnosed with stage IV HER2 -amplified esophagogastric cancer in January 2012 after presenting with dysphagia and back pain demonstrating vertebral metastases. The patient had
Stephanie L. Lee
of 1) increasing the sensitivity of long-term monitoring of thyroglobulin levels, 2) staging with posttherapy whole-body scan to detect local and distant metastases, and 3) facilitating the effectiveness of subsequent 131 I treatments if a large
